Trials / Unknown
UnknownNCT05705583
A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials showning better response in unselected patients with metastatic renal cell carcinoma (RCC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 RCC responsiveness. The objective of this study is to develop and evaluate the utility of circulating exosomes as companion diagnostic biomarker for predicting response to immunotherapy in patients with RCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Other: Blood and Urine Collection | Blood and Urine Collection |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2023-01-31
- Last updated
- 2023-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05705583. Inclusion in this directory is not an endorsement.